Table 3.
0 min | 20 min | 40 min | 60 min | 80 min | 100 min | 120 min | |
---|---|---|---|---|---|---|---|
Control | 2.41 ± 0.68 | 2.5 ± 0.83 | 2.58 ± 1.05 | 2.77 ± 1.57 | 2.31 ± 0.77 | 2.88 ± 0.98 | 3.36 ± 0.69 |
Mesendogen | 0.77 ± 0.41 * | 0.71 ± 0.35 * | 0.83 ± 0.43 * | 0.83 ± 0.38 | 1.05 ± 0.52 | 1.12 ± 0.47 * | 1.2 ± 0.62 * |
AG1478 | 1.66 ± 0.71 * | 1.49 ± 0.72 * | 1.83 ± 1.04 | 1.69 ± 0.64 | 1.59 ± 0.55 | 1.90 ± 0.69 * | 2.23 ± 0.86 * |
Dapagliflozin | 3.87 ± 1.85 * | 3.36 ± 2.53 | 4.20 ± 2.74 * | 3.58 ± 1.52 * | 3.31 ± 0.62 | 3.92 ± 0.76 * | 6.03 ± 1.84 * |
Dapagliflozin+Mesendogen | 0.60 ± 0.39 * | 0.58 ± 0.38 * | 0.67 ± 0.42 * | 0.64 ± 0.34 | 0.73 ± 0.45 | 0.68 ± 0.36 * | 0.84 ± 0.57 * |
Dapagliflozin+AG1478 | 0.67 ±0.70 * | 0.62 ± 0.65 | 0.73 ± 0.76 * | 0.65 ± 0.77 | 0.84 ± 0.95 * | 0.86 ± 1.01 | 0.91 ± 0.95 * |
* p < 0.05 vs. control.